Reference
1. McNeill A, Robson D. A man before his time: Russell’s insights into
nicotine, smoking, treatment and curbing the smoking problem.Addiction (Abingdon, England). 2018;113(4):759-763.
2. R W. Background smoking cessation rates in England. 2006.
http://www.smokinginengland.info/Ref/paper2.
3. Powles J, Day N. Interpreting the global burden of disease.Lancet (London, England). 2002;360(9343):1342-1343.
4. Kuper H, Tzonou A, Kaklamani E, et al. Tobacco smoking, alcohol
consumption and their interaction in the causation of hepatocellular
carcinoma. International journal of cancer. 2000;85(4):498-502.
5. Lowenfels AB, Maisonneuve P, Cavallini G, et al. Prognosis of chronic
pancreatitis: an international multicenter study. International
Pancreatitis Study Group. The American journal of
gastroenterology. 1994;89(9):1467-1471.
6. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol
and tobacco consumption on the risk of esophageal squamous cell
carcinoma: a meta-analysis. The American journal of
gastroenterology. 2014;109(6):822-827.
7. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of
abstinence: findings from the VA Normative Aging Study. Nicotine
& tobacco research : official journal of the Society for Research on
Nicotine and Tobacco. 2002;4(1):95-100.
8. Grucza RA, Bierut LJ. Cigarette smoking and the risk for alcohol use
disorders among adolescent drinkers. Alcoholism, clinical and
experimental research. 2006;30(12):2046-2054.
9. Schorling JB, Gutgesell M, Klas P, Smith D, Keller A. Tobacco,
alcohol and other drug use among college students. Journal of
substance abuse. 1994;6(1):105-115.
10. Craig TJ, Van Natta PA. The association of smoking and drinking
habits in a community sample. Journal of studies on alcohol.1977;38(7):1434-1439.
11. Dawson DA. Drinking as a risk factor for sustained smoking.Drug and alcohol dependence. 2000;59(3):235-249.
12. Weitzman ER, Chen YY. The co-occurrence of smoking and drinking
among young adults in college: national survey results from the United
States. Drug and alcohol dependence. 2005;80(3):377-386.
13. Kahler CW, Spillane NS, Metrik J. Alcohol use and initial smoking
lapses among heavy drinkers in smoking cessation treatment.Nicotine & tobacco research : official journal of the Society for
Research on Nicotine and Tobacco. 2010;12(7):781-785.
14. Elfghi M, Jordan F, Sultan S, Tawfick W. Study within a trial
protocol: Same-day consent vs. delayed consent in a randomized trial.Journal of evidence-based medicine. 2020;13(3):246-248.
15. Xu C, Thabane L, Liu T, Borhan A, Sun X. Flexible piecewise linear
model for investigating dose-response relationship in meta-analysis:
Methodology, examples, and comparison. Journal of evidence-based
medicine. 2019;12(1):63-68.
16. Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane
Collaboration’s tool for assessing risk of bias in randomised trials.BMJ (Clinical research ed). 2011;343:d5928.
17. Li Y, Cao L, Zhang Z, et al. Reporting and methodological quality of
COVID-19 systematic reviews needs to be improved: an evidence mapping.Journal of clinical epidemiology. 2021;135:17-28.
18. Pan B, Ge L, Xun YQ, et al. Exercise training modalities in patients
with type 2 diabetes mellitus: a systematic review and network
meta-analysis. The international journal of behavioral nutrition
and physical activity. 2018;15(1):72.
19. Statacorp N, Statacorp L, Statacorp S, Statacorp L. Stata
Statistical Software: Release 13. 2013.
20. Grant RL. The uptake of Bayesian methods in biomedical
meta-analyses: A scoping review (2005-2016). Journal of
evidence-based medicine. 2019;12(1):69-75.
21. Bold KW, Zweben A, Fucito LM, et al. Longitudinal Findings from a
Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with
Comorbid Cigarette Smoking. Alcoholism, clinical and experimental
research. 2019;43(5):937-944.
22. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT.
Varenicline for tobacco-dependence treatment in alcohol-dependent
smokers: A randomized controlled trial. Drug and alcohol
dependence. 2018;184:12-17.
23. Zawertailo L, Ivanova A, Ng G, Le Foll B, Selby P. Safety and
Efficacy of Varenicline for Smoking Cessation in Alcohol-Dependent
Smokers in Concurrent Treatment for Alcohol Use Disorder: A Pilot,
Randomized Placebo-Controlled Trial. Journal of clinical
psychopharmacology. 2020;40(2):130-136.
24. Kahler CW, Cioe PA, Tzilos GK, et al. A Double-Blind Randomized
Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers
Seeking Smoking Cessation Treatment. Alcoholism, clinical and
experimental research. 2017;41(6):1201-1211.
25. Leggio L, Zywiak WH, Edwards SM, Tidey JW, Swift RM, Kenna GA. A
preliminary double-blind, placebo-controlled randomized study of
baclofen effects in alcoholic smokers. Psychopharmacology.2015;232(1):233-243.
26. O’Malley SS, Zweben A, Fucito LM, et al. Effect of Varenicline
Combined With Medical Management on Alcohol Use Disorder With Comorbid
Cigarette Smoking: A Randomized Clinical Trial. JAMA psychiatry.2018;75(2):129-138.
27. Anthenelli RM, Heffner JL, Wong E, et al. A Randomized Trial
Evaluating Whether Topiramate Aids Smoking Cessation and Prevents
Alcohol Relapse in Recovering Alcohol-Dependent Men. Alcoholism,
clinical and experimental research. 2017;41(1):197-206.
28. Johnson BA, Ait-Daoud N, Akhtar FZ, Javors MA. Use of oral
topiramate to promote smoking abstinence among alcohol-dependent
smokers: a randomized controlled trial. Archives of internal
medicine. 2005;165(14):1600-1605.
29. O’Malley SS, Krishnan-Sarin S, McKee SA, et al. Dose-dependent
reduction of hazardous alcohol use in a placebo-controlled trial of
naltrexone for smoking cessation. The international journal of
neuropsychopharmacology. 2009;12(5):589-597.
30. Kalman D, Herz L, Monti P, et al. Incremental efficacy of adding
bupropion to the nicotine patch for smoking cessation in smokers with a
recent history of alcohol dependence: results from a randomized,
double-blind, placebo-controlled study. Drug and alcohol
dependence. 2011;118(2-3):111-118.
31. Fucito LM, Toll BA, Wu R, Romano DM, Tek E, O’Malley SS. A
preliminary investigation of varenicline for heavy drinking smokers.Psychopharmacology. 2011;215(4):655-663.
32. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ.
Bupropion and nicotine patch as smoking cessation aids in alcoholics.Alcohol (Fayetteville, NY). 2007;41(5):381-391.
33. King A, Cao D, Vanier C, Wilcox T. Naltrexone decreases heavy
drinking rates in smoking cessation treatment: an exploratory study.Alcoholism, clinical and experimental research.2009;33(6):1044-1050.
34. Fridberg DJ, Cao D, Grant JE, King AC. Naltrexone improves quit
rates, attenuates smoking urge, and reduces alcohol use in heavy
drinking smokers attempting to quit smoking. Alcoholism, clinical
and experimental research. 2014;38(10):2622-2629.
35. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A
randomized, controlled trial of bupropion sustained-release for
preventing tobacco relapse in recovering alcoholics. Nicotine &
tobacco research : official journal of the Society for Research on
Nicotine and Tobacco. 2009;11(7):859-867.
36. Kishi T, Iwata N. Varenicline for smoking cessation in people with
schizophrenia: systematic review and meta-analysis. European
archives of psychiatry and clinical neuroscience. 2015;265(3):259-268.
37. Wu Q, Gilbody S, Peckham E, Brabyn S, Parrott S. Varenicline for
smoking cessation and reduction in people with severe mental illnesses:
systematic review and meta-analysis. Addiction (Abingdon,
England). 2016;111(9):1554-1567.
38. Yan P, Yao L, Li H, et al. The methodological quality of robotic
surgical meta-analyses needed to be improved: a cross-sectional study.Journal of clinical epidemiology. 2019;109:20-29.